In the present study, a series of benzoquinazolines (1-13) and their quinazoline analogues (14-17) were evaluated for their HCV-NS3/4A inhibitory activities using in vitro assay.
Recent studies have shown some benzoquinazolines as potent antiviral agents and promising HAV-3C protease inhibitors. Thus, HCV NS3/A4 protease inhibitors are one of the best therapeutic targets for the identification of novel candidate drugs. HCV NS3/A4 protease plays an essential role in HCV life cycle and replication. Hence, there is a persistent demand to design and optimize current HCV therapy and develop novel agents. Morbidity and mortality due to hepatitis C virus (HCV) is a globe health concern.
